![BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool](https://mms.businesswire.com/media/20170801006281/en/604221/4/AML_infographic_8117---FINAL.jpg)
BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool
![BusinessWire - Acacia Research Corp. - Acacia Technologies (ACTG) Acacia Research Corporation Board of Directors Files its Definitive Proxy Materials and Issues Letter to Stockholders | ResearchPool BusinessWire - Acacia Research Corp. - Acacia Technologies (ACTG) Acacia Research Corporation Board of Directors Files its Definitive Proxy Materials and Issues Letter to Stockholders | ResearchPool](https://mms.businesswire.com/media/20180514005603/en/657334/4/Acacia--1.jpg)
BusinessWire - Acacia Research Corp. - Acacia Technologies (ACTG) Acacia Research Corporation Board of Directors Files its Definitive Proxy Materials and Issues Letter to Stockholders | ResearchPool
![BusinessWire - Under Armour Inc. Class C (UA) JBL® and Under Armour® Deliver Versatile Athletic Headphone for All-Day Wear: UA Sport Wireless Flex | ResearchPool BusinessWire - Under Armour Inc. Class C (UA) JBL® and Under Armour® Deliver Versatile Athletic Headphone for All-Day Wear: UA Sport Wireless Flex | ResearchPool](http://mms.businesswire.com/media/20171206005312/en/628175/4/JBL-UA-Flex-Grey-Hero-1605x1605px.jpg)